Authors
- Filip Lončarić — University Hospital Centre Zagreb, Zagreb, Croatia — ORCID: 0000-0002-7865-1108
- Dora Fabijanović — University Hospital Centre Zagreb, Zagreb, Croatia — ORCID: 0000-0003-2633-3439
- Vedran Velagić — University Hospital Centre Zagreb, Zagreb, Croatia — ORCID: 0000-0001-5425-5840
- Nina Jakuš — University Hospital Centre Zagreb, Zagreb, Croatia — ORCID: 0000-0002-9346-6402
- Marijan Pašalić — University Hospital Centre Zagreb, Zagreb, Croatia — ORCID: 0000-0002-3197-2190
- Ivo Planinc — University Hospital Centre Zagreb, Zagreb, Croatia — ORCID: 0000-0003-0561-6704
- Davor Miličić — University Hospital Centre Zagreb, Zagreb, Croatia — ORCID: 0000-0001-9101-1570
- Maja Čikeš — University Hospital Centre Zagreb, Zagreb, Croatia — ORCID: 0000-0002-4772-5549
Keywords
advanced interatrial block, heart failure, heart failure with preserved ejection fraction, P wave morphology, surface electrocardiogram
DOI
https://doi.org/10.15836/ccar2017.357Full Text
Background : An advanced interatrial block (aIAB) is seen on the ECG as the combination of a P wave duration >120 ms and biphasic P wave morphology in the inferior leads. It is considered a marker of an electromechanically dysfunctional left atrium (LA) and hence a risk factor for supraventricular arrhythmias and heart failure (HF). ( 1 ) The aim of our pilot study is to explore aIAB as a potential marker for determining a clinically relevant subgroup of HF patients. Patients and Methods : An echocardiogram and a surface ECG were performed on a total of 51 HF patients in sinus rhythm (31 (61%) with HF with preserved ejection fraction (HFpEF), 20 (39%) with HF with reduced ejection fraction (HFrEF)) diagnosed per the current guidelines, and 20 sex-matched healthy controls. Echocardiographic parameters of LA structure and function were measured. ECG measurements were performed digitally with an electronic calliper. Results : Prevalence of aIAB was 11% (n=8) in the studied group, significantly greater in HFpEF patients, compared to HFrEF patients and healthy controls (88% vs. 0% vs. 12%, p=0.025, Figure 1 ). The HFpEF patients formed an aIAB HFpEF subgroup (n=7) that was compared to two control groups, both without P wave duration >120 ms or biphasic P wave morphology in the inferior leads: age- and sex- matched HFpEF patients (n=7) and sex-matched healthy controls (n=12). Based on this subanalysis, the aIAB patients had a significantly higher occurrence of paroxysmal atrial fibrillation (healthy controls vs. HFpEF controls vs. aIAB: 0% vs. 43% vs. 86%, p<0.0001, Table 1 ). This subgroup also had the largest LA volumes (26.6 (18.7, 29.6) vs. 37.6 (32.7, 54.1) vs. 46.4 (41.4, 50.6) ml/m2, healthy controls vs. HFpEF controls vs. aIAB, respectively, p<0.0001, Table 1 ) and lowest LA ejection fraction (57.8 (46.4, 66.7) % vs. 39.7 (31.0, 41.3) % vs. 34.6 (31.8, 44.6) %, healthy controls vs. HFpEF controls vs. aIAB, respectively, p=0.004, Table 1 ). Selection of the heart failure subgroups based on left ventricular ejection fraction, P wave duration and biphasic P waves in the inferior leads (n=51). aIAB – advanced interatrial block; HFpEF – heart failure with preserved ejection fraction; IQR – interquartile range, AF – atrial fibrillation; LVEF – left ventricular ejection fraction; LAVI – left atrial volume index; LAA – left atrial area; LAEF – left atrial ejection fraction; V max – maximal volume of the left atrium; V min – minimal volume of the left atrium; preA volume – volume of the left atrium at start of P wave on ECG. Variables in the table are described with a percentage or with the median and interquartile range. Conclusion : This pilot study relates aIAB to the HFpEF part of the HF spectrum. Significant differences in LA structural and functional characteristics suggest that aIAB may be a useful parameter for determining a clinically relevant subgroup of HFpEF patients, however an analysis of a larger patient cohort would be required to further establish these findings.